FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Regulatory Review Period for Bayers Aliqopa

[ Price : $8.95]

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Bayers Aliqopa (copanlisib ...

OMB Approves 18 Information Collections

[ Price : $8.95]

Federal Register notice: FDA posts a list of 18 information collections that have been approved by OMB.

MCM Annual Report Achievements

[ Price : $8.95]

FDA releases the 2022 medical countermeasures annual report covering 14 key agency activities to support the development of and ac...

FDA Keeps Concert Drugs Breakthrough Status

[ Price : $8.95]

FDA says Concert Pharmaceuticals deuruxolitinib can retain its breakthrough therapy designation to treat alopecia areata.

Galera Priority Review for Oral Mucositis Drug

[ Price : $8.95]

FDA accepts for priority review a Galera Therapeutics NDA for avasopasem manganese for radiotherapy-induced severe oral mucositis ...

Court Action on 3 Claims Explained

[ Price : $8.95]

The latest Foley Hoag product liability update covers a Massachusetts federal courts ruling on three aspects of a case involving C...

Pediatric Drug Extrapolation in U.S. Analyzed

[ Price : $8.95]

Researchers say the use of pediatric extrapolation in a six-year period increased the rate of new and expanded pediatric indicatio...

Bryan Concerns About Gene Therapy Accelerated OKs

[ Price : $8.95]

The outgoing director of the CBER Office of Tissues and Advanced Therapies, Wilson Bryan, expresses concern about the length of co...

Sunrise At-Home Sleep Apnea Test Cleared

[ Price : $8.95]

FDA clears a 510(k) submitted by Belgium-based Sunrise for its second generation at-home sleep apnea test that uses artificial int...

FDA Facing Backlog of ODE Determinations: Attorneys

[ Price : $8.95]

Two Morgan Lewis attorneys explore decisions facing FDA in light of an 11th Circuit Court of Appeals ruling on orphan drug exclusi...